Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation

Transplantation

Volumn 65, Issue 8, 1998, Pages 1044-1046

  Zervos, Xaralambos A ^a,b   Weppler, Deborah ^a   Fragulidis, Georgios P ^a   Torres, Maria B ^a   Nery, Jose R ^a   Khan, Mohammed F ^a   Pinna, Antonio D ^a   Kato, Tomoaki ^a   Miller, Joshua ^a   Rajender Reddy, K ^c   Tzakis, Andreas G ^a  

^a School of Medicine   (United States)

^b University of Miami ^*  (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN A; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT INFECTION; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS DETECTION;

ADULT; AGED; CYCLOSPORINE; EMULSIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; REOPERATION; RNA, VIRAL; SURVIVAL RATE; TACROLIMUS;

EID: 0032571847     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199804270-00006     Document Type: Article

References (14)

1. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. Transplantation 1995; 59: 31.
2. Scheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30.
3. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317.
4. Schluger LK, Scheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971.
5. Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. Surgery 1996; 119: 452.
6. Chazouilleres O, Wright TL. Hepatitis C and liver transplantation. J Gastroenterol Hepatol 1995; 10: 471.
7. Neiblum DR, Boynton RF. Evaluation and treatment of chronic hepatitis C infection. Gastroenterology 1996; 23: 535.
8. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Int Med 1996; 125: 658.
9. McHutchison JG, Wilkes LB, Pockros PJ, et al. Pulse corticosteroid therapy increases viremia (HCV RNA) in patients with chronic HCV infection. Hepatology 1993; 18: 87.
10. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056.
11. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991; 23: 3105.
12. Mueller AR, Platz KP, Bechstein WO, et al. Increased rejection after liver transplantation in FK506-treated patients is associated with viral hepatitis C disease. Transplant Proc 1994; 26: 3637.
13. Mueller AR, Platz KP, Christe W, Bechstein WO, Blumhardt G, Neuhaus P. Severe neurotoxicity after liver transplantation: association between FK506 therapy and hepatitis C virus disease. Transplant Proc 1994; 26: 3131.
14. U.S. Multicenter Liver Study Group (Porayko MF, Gonwa TA, Klintmalm GB, Wiesner RH). Comparing nephrotoxicity of FK506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter Trial. Transplant Proc 1995; 27: 1114.